降糖保肾方对早期糖尿病肾病患者氧化应激的影响

The effects of Jiangtangbaoshenfang to patients with early diabetic nephropathy in oxidative stress

目的:研究降糖保肾方对早期糖尿病肾病氧化应激的影响,探讨降糖保肾方治疗早期糖尿病肾病的作用机制。方法:将符合纳入标准的72例患者,随机分为西药组(X组),中药组(Z组)。分别予厄贝沙坦150mg/次,1次/d,口服;降糖保肾方(免煎剂)每日2剂,口服;维持治疗8周,观察治疗前后血糖、蛋白尿、血清超氧化物岐化酶(SOD)、过氧化氢酶(CAT)、丙二醛(MDA)变化。结果:治疗8周后,降糖保肾方组空腹血糖显著下降至(8.4±1.0)mmol/L、餐后2h血糖显著下降至(12.1±1.4)mmol/L、HbA1c显著下降至(8.0±0.3)%(P<0.05);24h尿蛋白显著下降至(185.6±17.7)mg,24h尿微量清蛋白排泄率显著下降至(54.2±7.9)μg/min(P<0.05);SOD显著升高至(80.0±8.7)nU/ml、CAT显著升高至(26.4±2.4)nU/ml,MDA显著下降至(5.1±0.4)nmol/ml(P<0.05)。结论:降糖保肾方具有抗氧化作用,可能通过抑制氧化应激发挥保护糖尿病肾病的作用。

Objective： To study the effects of Jiangtangbaoshenfang to early diabetic nephropathy in oxidative stress and to explore the treating mechanism of Jiangtangbaoshenfang to early diabetic nephropathy. Methods： 72 patients who met the inclusion criteria were randomly divided into western medicine group （X group） and traditional chinese medicine group （Z group）. The patients of X group were given oral irbesartan 150 mg per time, one time per day, the patients at Z group were given oral Jiangtangbaoshenfang 2 did per day. The changes of the blood glucose, proteinuria, serum ultra-dismutase （SOD）, catalase （CAT）, malondialdehyde （MDA） were analyzed before and after 8 weeks treatment. Results： After 8 weeks, Jiangtangbaoshenfang significantly decreased fasting blood glucose to （8.4±1.0） mmol/L, decreased 2 hour postprandial blood glucose to （12.1±1.4） mmol/L, decreased HbA1c to （8.0±0.3）%, decreased 24 hour urine protein to （185.6±17.7） mg, decreased 24 hour urinary albumin excretion rate to （54.2±7.9） μg/min and MDA to （5.1±0.4） nmol/ml （P0.05）; and significantly increased SOD to （80.0±8.7） nU/ml and CAT to （26.4±2.4） nU/ml （P0.05）. Conclusion： Jiangtangbaoshenfang can protect diabetic nephropathy by inhibiting oxidative stress.